Amgen Breakthrough Sheds Light on Obesity Drug Paradox

Amgen researchers have made a significant discovery in obesity drug development, shedding light on a long-standing paradox. The team found that blocking a hormone called GIP can aid weight loss, despite activating the same hormone appearing to work as well.

This is a crucial issue for Amgen, which is testing an obesity therapy that mimics the GLP-1 hormone while blocking GIP. In contrast, Eli Lilly & Co.'s blockbuster Zepbound activates both hormones.

The finding could have significant implications for the development of new weight-loss treatments. If confirmed, it could lead to more effective and targeted therapies for obesity.